SCHEMBL7624972

SCHEMBL7624972

NC(=O)CN(C(=O)OCc1ccccc1)c1ccc(O)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.49
ALDH1A1 P00352 4/20 0.47
MAPT P10636 1/20 0.47
HPGD P15428 1/20 0.47
CA12 O43570 1/20 0.43
AKR1B10 O60218 1/20 0.43
AKR1B1 P15121 1/20 0.43
CA4 P22748 1/20 0.43
CA6 P23280 1/20 0.43
CA5A P35218 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
CA14 Q9ULX7 1/20 0.43
CA5B Q9Y2D0 1/20 0.43
CCR6 P51684 1/20 0.42
PAX8 Q06710 1/20 0.42
TDP1 Q9NUW8 2/20 0.41
MAPK1 P28482 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
SLC6A2 P23975 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1270807 0.88 LMNA (0.51) LMNAALDH1A1MAPTHPGDCA12
SCHEMBL11274033 0.83 LMNA (0.47) LMNAALDH1A1MAPTHPGDCA12
SCHEMBL10915717 0.82 LMNA (0.47) LMNAALDH1A1MAPTHPGDCA12
SCHEMBL84134 0.80 ALDH1A1 (0.49) LMNAALDH1A1MAPTHPGDCCR6
SCHEMBL8905179 0.80 ALDH1A1 (0.47) LMNAALDH1A1MAPTHPGDCCR6
SCHEMBL11732537 0.80 ALDH1A1 (0.42) LMNAALDH1A1MAPTHPGDENPP2
SCHEMBL11790891 0.79 ALDH1A1 (0.48) LMNAALDH1A1MAPTHPGDCCR6
SCHEMBL7627031 0.79 ALDH1A1 (0.49) LMNAALDH1A1MAPTHPGDTDP1
SCHEMBL7350797 0.78 ALDH1A1 (0.49) LMNAALDH1A1MAPTHPGDCCR6
SCHEMBL11274016 0.77 TDP1 (0.49) LMNAALDH1A1MAPTHPGDTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020061839-A1 Serine peptidase modulators SCHARPE SIMON LODEWIJK (BE) 2002-05-23 US disclosed
EP-1062222-A1 SERINE PEPTIDASE MODULATORS Fondatech Benelux N.V. (BE) 2000-12-27 EP disclosed
WO-1999046272-A1 SERINE PEPTIDASE MODULATORS FONDATECH BENELUX N.V. (BE) 1999-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061839-A1 Serine peptidase modulators FAP, CTSC, DPP4 LMNA 3159/4885ALDH1A1 2096/4885MAPT 3116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.